Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Trading Up 3.5 %

Shares of NERV stock opened at $2.36 on Friday. The company has a market cap of $16.50 million, a P/E ratio of -5.36 and a beta of 0.11. The firm has a fifty day moving average price of $2.26 and a 200 day moving average price of $2.65. Minerva Neurosciences has a 12 month low of $2.06 and a 12 month high of $13.49.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.